

Teaching Pearls in Noninvasive Mechanical Ventilation

Key Practical Insights

Antonio M. Esquinas
Editor

MOREMEDIA 

 Springer

Teaching Pearls in Noninvasive Mechanical Ventilation

Antonio M. Esquinas
Editor

Teaching Pearls in Noninvasive Mechanical Ventilation

Key Practical Insights

 Springer

Editor

Antonio M. Esquinas
Intensive Care Unit
Hospital Morales Meseguer
Murcia, Spain

ISBN 978-3-030-71297-6 ISBN 978-3-030-71298-3 (eBook)
<https://doi.org/10.1007/978-3-030-71298-3>

© Springer Nature Switzerland AG 2022

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

To my family..., great motivation in my live

Preface

In the last decades, we have developed a broad knowledge base in noninvasive mechanical ventilation that supports the daily use of this technique in different settings and medical specialties. We have been able to establish solid knowledge and apply practical protocols as well as technological advances. From a critical perspective, one of these essential elements that have allowed us to ensure a correct application is supported by excellence in training and education plans in noninvasive mechanical ventilation carried out with the support of clinical teachers. In this original and first book, **Teaching Pearls in Noninvasive Mechanical Ventilation**, we offer the first original book whose bases is a teaching based on the critical analysis of selected clinical cases that represent the most common and real situations of use of noninvasive mechanical ventilation.

The structure of the book and chapters is based on the teaching that provides the critical analysis of the most common clinical cases present on a daily basis of clinical practice. This original book structure makes it ideal to be a reference book in training and education plans of pulmonary as well as critical care and sleep medicine fellowship programs, universities, and postgraduate courses in noninvasive mechanical ventilation. This book comes from the solid idea that teaching based on the “critical analysis” of the “clinical case” is the first and basic element to ensure the best transmission of knowledge and correct application. Besides, this book is conceived as a key tool for proper teaching for professors or teachers in the field of **Noninvasive Mechanical Ventilation**.

If you want to learn, teach (Marcus Tullius Ciceron)

Murcia, Spain
March 2021

Antonio M. Esquinas

Contents

Part I Clinical Cases in Noninvasive Ventilation: Interfaces, Methodology

1	Facemask and Total Face Mask	3
	Edoardo Piervincenzi, Giorgio Zampini, and Daniela Perrotta	
	1.1 Introduction	3
	1.2 NIV-Mask.	4
	1.2.1 Characteristics	4
	1.3 Bronchopulmonary Displasia.	8
	References.	10
2	Helmet	13
	Giorgio Zampini, Edoardo Piervincenzi, and Daniela Perrotta	
	2.1 Introduction	13
	2.2 Helmet Interface.	14
	2.3 Bronchiolitis.	15
	References.	18
3	Mouthpiece Ventilation	21
	Jennifer Obi and Stephen M. Pastores	
	3.1 Introduction	22
	3.2 Types of Mouth Piece Interfaces	22
	3.3 Indications	23
	3.4 Mechanisms	24
	3.5 Advantages.	24
	3.6 Disadvantages and Contraindications	24
	3.7 Conclusions	26
	References.	26
4	Discomfort and Adaptation in Non Invasive Mechanical Ventilation: Mask Interface Problems	27
	Alejandro Úbeda Iglesias, Irene Fernández Burgos, and Rosario Ana Torcuato Barrera	

4.1	Choosing the Interface	28
4.2	Problems Related to the Interface	29
	References.	33
5	Discomfort and Adaptation. Mask Interface Problems.	35
	Jennifer Obi and Stephen M. Pastores	
5.1	Principles of Management	36
	5.1.1 Introduction	36
5.2	Interface Selection	36
5.3	Types of Interfaces	37
5.4	Mask Interface Problems and Solutions	38
	5.4.1 Mask Claustrophobia	38
	5.4.2 Aerophagia	40
	5.4.3 Sore Nose, Skin Irritation and Ulcers	41
	5.4.4 Air leaks	41
	5.4.5 Carbon Dioxide Rebreathing	42
	5.4.6 Nasal or Oral Dryness and Nasal Congestion	42
	5.4.7 Eye Irritation	43
	5.4.8 Noise	43
	References.	44
6	Unusual Facial Muscle Atrophy Associated with Noninvasive Ventilation	47
	Antônio Madeira Gerardo, Maria Inês da Luz Ferreira, Carla Filipa Alves Simão Valente, and Hedi Esteves Sequeira Liberato	
6.1	Introduction	47
6.2	Clinical Case	48
6.3	Discussion	50
	References.	52
7	Noninvasive Ventilation: Continuous Positive Air Pressure Ventilation (CPAP) and Pressure Support Ventilation (PSV)	53
	Edoardo Piervincenzi, Giorgio Zampini, and Daniela Perrotta	
7.1	Introduction	54
7.2	Mechanical Ventilation in IPF: Basic Topics	55
7.3	Non-invasive Ventilation (NIV)	56
	7.3.1 NIV Mode: PSV vs. CPAP	57
	7.3.2 NIV Interface: Helmet vs. Face—Mask	58
7.4	Summary	60
	References.	61
8	Continuous Positive Airway Pressure	65
	Uğur Özdemir	
8.1	Introduction	67
8.2	Indications	68

- 8.3 Use of CPAP in the pulmonary Edema due to Congestive Heart Failure 68
- 8.4 Use of CPAP in the Obesity-Hypoventilation Syndrome 69
- 8.5 Use of CPAP in the Obstructive Sleep Apnea Syndrome 69
- 8.6 Use of CPAP in the Perioperative Period. 70
- 8.7 Contraindications. 71
- References. 71

- 9 How Do Hybrid Pressure Ventilation Modes Respond to Patient’s Varying Ventilatory Requirements? Insights from Respiratory Bench Simulations 73**
 Kaixian Zhu, Charles-Philippe Thevenin, Claudio Rabec, and Sébastien Hardy
 - 9.1 Introduction 73
 - 9.2 Volume-Assured Pressure Support (VAPS) Ventilation. 74
 - 9.3 VAPS Ventilation with Autotitrating Expiratory Positive Airway Pressure (EPAP) 78
 - References. 83

Part II Clinical Cases and Noninvasive Ventilation Physiology

- 10 Noninvasive Ventilation Extrapulmonary Response Determinants 87**
 Aysun Dauti Isiklar
 - 10.1 Introduction 88
 - 10.2 Effects of Positive Pressure Ventilation (PPV) on Thoracic Functions 88
 - 10.3 Increased Pulmonary Vascular Resistance and Altered Right and Left Ventricular Function 88
 - 10.4 The Effect of Positive Pressure Ventilation on Coronary Blood Flow. 89
 - 10.5 Factors Determining Cardiovascular Effects of Positive Pressure Ventilation 89
 - 10.6 Indemnity in Individuals with Normal Cardiovascular Function 89
 - 10.7 Beneficial Effects of Positive Pressure Ventilation on Heart Function in Patients with Left Ventricular Dysfunction 90
 - 10.8 Effects of Mechanical Ventilation on Intracranial Pressure and Cerebral Perfusion. 90
 - 10.9 Renal Effects of Mechanical Ventilation 90
 - 10.10 The Effect of Mechanical Ventilation on Liver and Gastrointestinal Functions 92
 - 10.11 Nutritional Problems During Mechanical Ventilation 93
 - References. 96

11	Patterns Response (Apnea, Hypopnea, Tachypnea)	99
	Aysun Dauti Isiklar	
	11.1 Introduction	99
	11.2 Types of Clinical Pattern Response	100
	References.....	101
12	Lung Mechanics- Compliance and Resistance-Extrapulmonary Response	103
	Aylin Özdilek	
	12.1 Introduction	104
	12.2 Resistance	104
	12.2.1 Tissue Resistance.....	104
	12.2.2 Airway Resistance.....	104
	12.3 Compliance	106
	12.3.1 Chest Wall Compliance	107
	12.4 Lung Compliance.....	107
	12.5 Clinical Vignette.....	108
	References.....	109
Part III Clinical Cases and Noninvasive Ventilation Pattern Response		
13	Early and Late Failure During Noninvasive Ventilation	113
	Aslihan Gürün Kaya, Aydın Çiledağ, and Akın Kaya	
	13.1 Introduction	114
	13.2 Discussion	116
	References.....	119
14	Noninvasive Ventilation. Rebreathing	121
	Fabrizio Rao and Elisa Falcier	
	14.1 Introduction	121
	14.2 Discussion	124
	References.....	127
15	Bilateral Pneumothorax in Neuromuscular Disease Associated with Noninvasive Ventilation and Mechanical Insufflation-Exsufflation	129
	Antônio Madeira Gerardo, Maria Inês da Luz Ferreira, Carla Filipa Alves Simão Valente, and Hedi Esteves Sequeira Liberato	
	15.1 Introduction	129
	15.2 Discussion	131
	References.....	133
16	Early and Late Failure During Noninvasive Ventilation	135
	Matthew Ballenberger and Bhusra Mina	
	16.1 Introduction	136
	16.2 Immediate Failure	136

16.2.1	Should These Patients Receive a Trial of NIV?	137
16.2.2	Initiating NIV: Location	137
16.2.3	Initiating NIV: Settings and Interface	138
16.3	Early Failure	138
16.4	Late Failure	139
16.5	Predictive Scores	141
16.6	Discussion and Practical Implications	142
	References	145
Part IV Noninvasive Ventilation Interaction, Monitoring and Methodology		
17	Patient Ventilator Asynchrony	149
	Alejandro Úbeda Iglesias, Irene Fernández Burgos, and Rosario Ana Torcuato Barrera	
17.1	Trigger Asynchrony	150
17.2	Flow Asynchrony	152
17.3	Cycle Asynchrony	152
	References	154
18	Patient Ventilator Asynchrony	155
	Lazzeri Marta and Spadaro Savino	
18.1	Introduction	156
	References	163
19	Clinical Cases in Non Invasive Ventilation: Pressure Waveform	165
	Ana Cláudia Vieira and António Miguel Silveira	
19.1	Clinical Cases in Non Invasive Ventilation: Pressure Waveform	165
19.1.1	Standard Clinical Case	165
19.2	Discussion	167
	References	170
20	Pressure Waveform. Clinical Interpretation - Acute Respiratory Failure in COPD	171
	Giuseppe Fiorentino, Anna Annunziata, and Pasquale Imitazione	
20.1	Discussion	174
20.2	Waveform Analysis	176
20.3	Pressure Support Level	177
20.4	Leaks	179
20.5	Inspiratory Trigger	179
20.6	Cycling from Inspiration to Expiration	180
20.7	Expiratory Asynchrony	181
20.7.1	Delayed Cycling	181
20.8	Conclusion	182
	References	184

21 Intensive Care Unit Ventilators Some Aspects in Noninvasive Mechanical Ventilation	185
Ebru Ortac Ersoy	
21.1 Introduction	185
21.2 Discussion	187
References	189
Part V Clinical Cases in Noninvasive Ventilation: NIV in Procedures Applications	
22 Non Invasive Mechanical Ventilation and Echocardiographic	193
Dusanka Obradovic and Uros Batranovic	
22.1 Introduction	194
References	201
23 Lung and Diaphragm Ultrasound for Monitoring Patient's Ongoing Non-invasive Mechanical Ventilation	203
Eva M. Tenza-Lozano	
23.1 Introduction	204
23.2 Complementary Explorations	204
23.3 Discussion	205
References	209
24 Non Invasive Mechanical Ventilation and Bronchoscopy	211
Carmine D. Votta, Margherita Tozzi, and Giovanni Landoni	
24.1 Introduction	211
24.2 Conclusions	213
References	215
25 Clinical Cases in Noninvasive Ventilation: NIV in Procedures Applications. Bronchoscopy	217
Szymon Skoczyński and Łukasz Minarowski	
25.1 Discussion	221
References	224
Part VI Clinical Conditions: Acute Hypoxemic Respiratory Failure	
26 Noninvasive Ventilation in Hematology-Oncology Patients with Acute Respiratory Failure	227
Sammar R. Alsunaid and Ayman O. Soubani	
26.1 Introduction	228
26.2 Noninvasive Ventilation	229
26.3 High Flow Oxygen Therapy	231
26.4 Conclusion	232
References	232

27	Treatment of Acute Respiratory Failure in Patient with Congestive Heart Failure and Pneumonia	235
	Biljana Joves	
	27.1 Introduction	236
	References.	240
28	Neurally Adjusted Ventilator (NAVA) Mode	241
	Martin Scharffenberg and Jakob Wittenstein	
	28.1 Introduction	242
	28.2 Clinical Course.	242
	28.2.1 Indications and Contraindications of NAVA	243
	28.2.2 Patient Interfaces	243
	28.2.3 Placement of the NAVA-Catheter	244
	28.2.4 Initiation of NAVA.	245
	28.2.5 Ventilator Settings: Adjusting and Maintaining NIV-NAVA.	245
	28.2.6 Alternative Ways of Setting NIV-NAVA	246
	28.2.7 Subject Ventilator Asynchrony.	247
	28.2.8 The Diagnostic Value of the EADi Signal	248
	28.2.9 Weaning with and from NAVA	249
	References.	250
29	Non-invasive Mechanical Ventilation in Pneumonia	253
	Maria Joana Pereira	
	29.1 Introduction	253
	29.2 Discussion	255
	References.	260
30	Non Invasive Ventilation in High Risk Infections	261
	Maria Joana Pereira and Sónia André	
	30.1 Introduction	262
	30.2 Discussion	263
	References.	268
31	Clinical Conditions—Acute Hypoxemic Respiratory Failure: Non Invasive Ventilation in Pneumonia	269
	Christos Triantafyllou and Pavlos M. Myrianthefs	
	31.1 Introduction	270
	31.2 Acute Hypoxemic Respiratory Failure Due to Pneumonia and Non-invasive Ventilation	271
	References.	277
32	Non Invasive Ventilation in Asthma Exacerbation	279
	Burhan Sami Kalın	
	32.1 Introduction	280
	32.2 Discussion	283
	References.	285

33 Unusual Case of Acute Pulmonary Edema Treated by Non Invasive Ventilation: A 30 Years Ago “Cold Case”! 287
 Corrado Mollica, Giovacchino Pedicelli, Savino Spadaro, and Massimo Pistolesi

33.1 Introduction 288

33.2 Discussion 292

 33.2.1 Formation and Resolution of Edema 292

 33.2.2 Detection Methods 293

 33.2.3 Ventilatory Therapy 296

 33.2.4 Outcome 298

33.3 Limits of the Present Contribution 298

33.4 Conclusions 299

References 301

34 Non Invasive Ventilation in Acute Cardiac Pulmonary Edema 305
 G. Moreno-Gonzalez and N. D. Toapanta-Gaibor

34.1 Introduction 306

34.2 Physiopathology of Pulmonary Edema of Cardiogenic Origin and Effects of Positive Airway Pressures 307

34.3 Respiratory Support in Acute Cardiac Pulmonary Edema 310

34.4 Concluding Remarks 314

Suggested Reading 314

35 Clinical Conditions Acute Hypoxemic Respiratory Failure: Non Invasive Ventilation in Thoracic Trauma 315
 Fabrizio Bottino

References 319

36 Thoracic Surgery, a Clinical Case in Non-invasive Ventilation: Clinical Conditions in the Perioperative Period. 321
 Jakob Wittenstein and Martin Scharffenberg

36.1 Introduction 321

36.2 The Teaching Case 323

36.3 Preoperative Phase 323

36.4 Intraoperative Phase 325

36.5 Postoperative Phase 326

References 328

37 Non-invasive Ventilation Following Thoracotomy: Clinical Case 331
 Yerosimou Fotis and Schizas Nikolaos

37.1 Introduction 332

37.2 Discussion 334

References 335

38 Noninvasive Ventilation in Acute Respiratory Distress Syndrome 337
 Julie Lin and John P. Kress

References 344

39 Nasal High Flow Oxygen During Post-extubation Period in a Patient with Traumatic Brain Injury 345
 Sibel Ocak Serin and Gulsah Karaoren
 39.1 Introduction 345
 39.2 Conclusion 349
 References. 349

Part VII Clinical Conditions: Sleep Breathing Disorders

40 Treatment-Emergent Central Sleep Apnea: Always Look for an Air Leak 353
 Abdul Rouf Pirzada and Ahmed Salem BaHamman
 40.1 Introduction 353
 40.2 Discussion 354
 40.2.1 Pathophysiology of TECSA. 356
 40.2.2 Time-Course of TECSA. 358
 40.2.3 Treatment 358
 References. 360

41 Non Invasive Ventilation in Sleep Apnea Syndrome 361
 C. M. Acosta Gutiérrez, C. Matesanz López, and J. Montoro Ruiz
 References. 366

42 Nocturnal Hypoventilation and Sleep Breathing Disorders 369
 David Barros Coelho
 42.1 Definitions 370
 42.2 Pathophysiology of Hypoventilation During Sleep. 371
 42.3 Clinical Presentation and Evaluation 372
 42.4 Classification and Causes of Sleep Related Hypoventilation 372
 42.4.1 OHS 373
 42.4.2 CCHS 373
 42.4.3 Late Onset Central Hypoventilation with Hypothalamic Dysfunction 374
 42.4.4 Neuromuscular Disorders 374
 42.4.5 Kyphoscoliosis. 374
 42.4.6 Medication 374
 42.4.7 Heart Failure 375
 42.5 Treatment 375
 42.6 Discussion of Case. 376
 References. 376

43 Non Invasive Ventilation: Nocturnal Hypoventilation and Sleep Breathing Disorders 379
 Alexandra C. Gavala and Pavlos M. Myrianthefts
 43.1 Introduction 380
 43.2 Clinical Case of OHS Coexisting with OSA 381
 43.2.1 What Is the Diagnosis? 382

- 43.2.2 What Is the Next Step? 384
- 43.2.3 Which Is Better Therapy Option: CPAP or NPPV? 385
- 43.2.4 What to Expect after Short-Term PAP Therapy Initiation? 389
- 43.2.5 Lifestyle Changes—Weight Loss: Does it Matter? 389
- References. 392

**Part VIII Clinical Conditions: Chronic Hypercapnic
Respiratory Failure**

- 44 Noninvasive Ventilation in Chronic Obstructive
Pulmonary Disease: Ventilating the Patient with Severe
Respiratory Acidosis 397**
Biljana Joves
 - 44.1 Introduction 398
 - References. 403
- 45 Noninvasive Ventilation in Chronic Obstructive
Pulmonary Disease 405**
Maria Joana Pereira and Maria João Matos
 - 45.1 Introduction 405
 - 45.2 Discussion 408
 - References. 410
- 46 Non-invasive Ventilation in Adults with Cystic Fibrosis 411**
Giulia Spoletini
 - 46.1 Introduction 411
 - 46.2 Discussion 414
 - 46.2.1 Indications 415
 - 46.2.2 Contraindications and Complications of NIV in CF 417
 - 46.2.3 Starting NIV in CF. 418
 - 46.3 Conclusion 420
 - References. 421
- 47 Non Invasive Mechanical Ventilation in Idiopathic
Pulmonary Fibrosis: A Clinical Case 423**
Corrado Mollica, Angelo Petroianni, and Vittoria Conti
 - 47.1 Introduction 424
 - 47.2 Discussion 427
 - 47.3 Non-invasive Mechanical Ventilation in IPF 427
 - 47.4 Indication to Start MV in IPF 428
 - 47.5 Modes of MV 428
 - 47.6 Interfaces: Helmet vs. Facial Mask 429
 - 47.7 Predictors of MV Failure in IPF 430
 - 47.8 Conclusions 430
 - References. 432

48	Non Invasive Ventilation, Pulmonary Rehabilitation and Chest Physiotherapy-1	435
	Danijela Kuhajda, Dušanka Obradović, and Laura D. Ciobanu	
48.1	Introduction	436
48.2	Discussion	437
	References	443
49	Non Invasive Ventilation, Pulmonary Rehabilitation and Chest Physiotherapy-2	445
	Laura D. Ciobanu	
49.1	Brief Introduction to the Concept of Pulmonary Rehabilitation	446
49.2	Noninvasive Ventilation: Why to Think About It?	447
49.3	Types of NIV Useful in Association with Pulmonary Rehabilitation	449
49.3.1	Negative Airway Pressure Devices	449
49.3.2	Positive Airway Pressure Devices	449
49.3.3	Non-invasive Ventilation as an Adjunct to Pulmonary Rehabilitation	450
49.3.4	Pulmonary Rehabilitation and Noninvasive Ventilation in Acute Exacerbation of COPD	451
49.3.5	Pulmonary Rehabilitation and Noninvasive Ventilation in Stable COPD Patients	452
49.3.6	Pulmonary Rehabilitation and Noninvasive Ventilation at Home	454
49.3.7	Pulmonary Rehabilitation and Noninvasive Ventilation in Palliative Care Services	454
49.4	Conclusions	455
	References	456
50	Obesity Hypoventilation Syndrome	457
	David Barros Coelho	
50.1	Definitions	458
50.2	Epidemiology	459
50.3	Pathophysiology	459
50.4	Clinical Presentation and Diagnosis	460
50.5	Comorbidities	461
50.6	Treatment	461
50.7	Discussion of Case	462
	References	463
51	Elderly Non Invasive Mechanical Ventilation Applications	465
	Fatma Çiftci	
51.1	Introduction	465
51.2	Acute Respiratory Failure	466
51.3	Acute Cardiogenic Pulmonary Edema	466

51.4	Immunocompromised Elderly Patients	467
51.5	Palliative Care and DNI	467
51.6	Weaning	468
51.7	Home NIV in Elderly Patients	468
	References	469
52	Elderly-NIV: Non-invasive Mechanical Ventilation Treatment in Elderly Patient with Usual Interstitial Pneumonia	471
	María Pilar Martín-Fortea and Laura Anoro Abenoza	
52.1	Real Case Clinic	472
	52.1.1 Introduction	472
	52.1.2 Complementary Explorations	472
	52.1.3 Discussion	472
	References	476
53	Clinical Case in Non Invasive Ventilation in End of Life	477
	Nicola Vargas, Loredana Tibullo, Andrea Fabbo, and Antonio M. Esquinas	
53.1	Introduction	477
53.2	An Ill Cancer Patient Who Has Chosen NIV	478
53.3	Discussion	479
53.4	Conclusion	479
	References	481
54	Clinical Cases in Non Invasive Ventilation: Home Mechanical Ventilation	483
	Fatma Çiftci	
54.1	Introduction	483
54.2	Neuromuscular Diseases	483
54.3	Chest Wall Diseases	484
54.4	Chronic Obstructive Pulmonary Disease	485
54.5	Post-acute Exacerbation of COPD	485
54.6	COPD-OSA Overlap Syndrome	486
54.7	NIV in Bronchiectasis	486
54.8	NIV in Cystic Fibrosis	486
54.9	NIV in Obesity Hypoventilation	487
54.10	Palliative NIV	487
54.11	Ventilator Settings and Compliance	487
54.12	Selection of Interface	488
54.13	Conclusion	488
	References	489
55	Comorbidities Conditions Impact (Renal Failure/Liver Failure/ Neurologic) in Non Invasive Mechanical Ventilation	491
	Kamil İnci	
55.1	Introduction	491
55.2	Discussion	494
	References	497

56 Clinical Cases in Noninvasive Ventilation: Clinical Conditions—Hypercapnic Failure—Neuromuscular Disorders 499
 Maria Joana Pereira and Maria João Matos
 56.1 Introduction 499
 56.2 Discussion 502
 References. 504

57 Clinical Case in Noninvasive Ventilation: Clinical Conditions—Respiratory Care of Neuromuscular Disorders—A Rare Case of Charcot-Marie-Tooth Disease (CMT2S) 505
 Richa Kulshrestha, Tracey Willis, and Martin Samuels
 57.1 Introduction 506
 57.2 Discussion Based on Case Clinic. 506
 57.2.1 Development and Progress. 506
 57.2.2 Acute Deterioration of the Patient at 9 Years. 506
 57.2.3 Best Clinical Practice Statement from the Recommendations of British Thoracic Society Guidelines 509
 57.2.4 Nutrition. 510
 57.2.5 Orthotics. 511
 57.3 Summary 511
 References. 513

58 Clinical Case in Noninvasive Ventilation: Clinical Conditions—Hypercapnic Failure—Neuromuscular Disorders in Amyotrophic Lateral Sclerosis. 515
 Joana Barbosa, Sara Salgado, and Paula Esteves
 58.1 Introduction 516
 58.2 Discussion/Main Topic 517
 References. 521

59 Noninvasive Ventilation in Ventilatory Pump Failure: When Is Oxygen Administration Deadly? 523
 C. Matesanz López, C. M. Acosta Gutiérrez, and J. R. Bach
 59.1 Clinical Practice. 524
 References. 527

60 Clinical Case in Non Invasive Ventilation: Ethical Aspects of the Palliative Use. 529
 Andrea Fabbo, Marilena De Guglielmo, and Nicola Vargas
 60.1 Introduction 529
 60.2 Discussion 532
 60.3 Conclusion 533
 References. 535

- 61 Clinical Cases in Noninvasive Ventilation in Quality of Life. 537**
 - Toru Oga
 - 61.1 Introduction 537
 - 61.2 MRF 538
 - 61.3 SRI 539
 - 61.4 S³-NIV Questionnaire 540
 - 61.5 HRQL Scores in Patients Receiving the NIV: Clinical Cases 540
 - 61.6 Conclusion 541
 - References. 542

- 62 Pediatric Non-invasive Ventilation: Non-invasive Ventilation Treatment in a Pediatric Patient with Catathrenia 545**
 - David C. Earl, Steven A. Lopez, and Lee K. Brown
 - 62.1 Introduction 545
 - 62.2 Video-PSG Sleep Study Data. 546
 - 62.3 Discussion 546
 - References. 550

Abbreviations

AASM	American Academy of Sleep Medicine
ABG	Arterial blood gas analysis
ACBT	Active cycle of breathing technique
AChR-Ab	Autoantibodies against the acetylcholine receptor
ACPE	Acute cardiac pulmonary edema
ADH	Anti-diuretic hormone
AECOPD	Acute exacerbation of chronic obstructive pulmonary disease
AE-IPF	Acute exacerbation of IPF
AF	Atrial Fibrillation
AFC	Alveolar fluid clearance
AG	Anion gap
AHI	Apnea hypopnea index
AHRF	Acute hypoxemic respiratory failure
AI	Asynchrony index
AI%	Asynchrony index
AIH	Apnea hypopnea index
AKI	Acute kidney injury
ALI	Acute lung injury
ALS	Amyotrophic lateral sclerosis
ALT	Alanine aminotransferase
APACHE II	Acute Physiology and Chronic Health Evaluation II
APCV	Assist pressure control ventilation
APE	Acute pulmonary edema
ARDS	Acute respiratory distress syndrome
ARF	Acute respiratory failure
ASA	American Society of Anesthesiologists
AST	Aspartate aminotransferase
ASV	Adaptive servoventilation
ATS	American Thoracic Society
AUC	Area under the curve
AVAPS	Average volume-assured pressure support

Bf	Bronchofiberoscopy
BGA	Blood gas analysis
BiPAP	Bilevel positive airway pressure
BiPAP-S	BiPAP spontaneous mode
BMI	Body mass index
BNP	Brain natriuretic peptide
BP	Blood pressure
bpm	Beats per minute
C	Compliance
CAP	Community acquired pneumonia
CCHS	Congenital central alveolar hypoventilation syndrome
CF	Cystic fibrosis
CHRF	Chronic hypercapnic respiratory failure
CI	Confidence interval
CKD	Chronic kidney disease
CLD	Chronic liver disease
cm H ₂ O	Centimeter of water
CMO	Comfort measures only
CMT	Charcot–Marie–Tooth disease
CO ₂	Carbon dioxide
COPD	Chronic obstructive pulmonary disease
CPAP	Continuous positive airway pressure
CPE	Cardiogenic pulmonary edema
CPH	Chronic pulmonary hypertension
CPT	Chest physiotherapy
CRF	Chronic respiratory failure
CRP	C-reactive protein
CRX	Chest radiograph
CSA	Central sleep apnea
CT	Computed tomography
CTPA	Computed tomographic pulmonary angiography
CURB-65	Confusion, urea, respiratory rate, blood pressure – 65 years of age
CVP	Central venous pressure
CWP	Centimeters of water pressure
CXR	Chest X-Ray
DAD	Diffuse alveolar damage
DE	Diaphragmatic excursion
DEX	Dexmedetomidine
DLCO	Carbon monoxide diffusion capacity
DLT	Double lumen tube
DMD	Duchenne muscular dystrophy
DNI	Do-not-intubate
DNR	Do not resuscitate
DOT	Domiciliary oxygen therapy
DP	Driving pressure

DRG	Dorsal respiratory group
DT	Diaphragm thickness
e	Elastance
EAdi	Electrical activity of diaphragm
EADi/Edi	Electrical activity of the diaphragm
ECCO2R	Extracorporeal CO ₂ removal
ECG	Electrocardiogram
ECMO	Extracorporeal membrane oxygenation
ED	Emergency Department
EEN	Effective enteral nutrition
EF	Ejection fraction
EPAP	Expiratory positive airway pressure
ERS	European Respiratory Society
ES	Excessive sleepiness
OSAS	Obstructive Sleep Apnea Syndrome
IAH	Index of apnea-hypoapnea
PSG	Polysomnography
RSD	Respiratory sleep disorder
ESICM	European Society of Intensive Care Medicine
ESS	Epworth sleepiness scale
EVLW	Extra-vascular lung water
Flow	Gas flow
FBS	Fiberoptic bronchoscopy
FEF	Forced expiratory flow
FEV1	Forced expiratory volume in the first second
FEV1/FVC ratio	Forced expiratory volume in the first second/forced vital capacity
FiO ₂	Fraction of inspired oxygen
FM	Face-mask
FMV	Face-mask ventilation
FOB	Fiberoptic bronchoscopy
FRC	Functional residual capacity
FVC	Forced vital capacity
GCS	Glasgow Coma Scale
GOLD	Global Initiative for Chronic Obstructive Lung Disease
GORD	Gastro-oesophageal reflux disease
GPB	Glossopharyngeal breathing
HACOR	Heart rate, Acidosis, Consciousness, Oxygenation, and Respiratory rate
HAP	Hospital-acquired pneumonia
Hb	Hemoglobin
HCO ₃ ⁻	Bicarbonate
HDU	High Dependency Unit
HES	Hypercapnic encephalopathy syndrome
HFNC	High flow nasal cannula

HINPPV	High-intensity noninvasive positive pressure ventilation
HR	Heart rate
HRCT	High-Resolution Computed Tomography
HRQoL	Health-Related Quality of Life
Htc	Hematocrit
IAP	Intra-abdominal pressure
IBP	Invasive blood pressure
IBW	Ideal body weight
IC	Inspiratory capacity
ICP	Intracranial pressure
ICS	Inhaled corticosteroid
ICSD-3	International Classification of Sleep Disorders, Third Edition
ICU	Intensive Care Unit
I:E Ratio	Ratio of inspiratory and expiratory time
IGHMBP2	Immunoglobulin helicase μ -binding protein 2
ILD	Interstitial lung disease
IMV	Invasive mechanical ventilation
IPAP	Inspiratory positive airway pressure
IPF	Idiopathic pulmonary fibrosis
IPPB	Intermittent positive pressure breathing
ISS	Injury Severity Score
IT	Inspiratory time
IV	Intravenous
IVS	Interventricular septum
KMS	Kelly-Matthay Scale
L/min	Liter per minute
LA	Left atrial
LABA	Long-acting β_2 -agonist
LAMA	Long-acting muscarinic antagonist
LMWH	Low molecular weight heparin
LoS	Length of stay
LRTI	Lower respiratory tract infection
LTMV	Long-term mechanical ventilation
LTOT	Long-term oxygen therapy
LUS	Lung ultrasound
LUS-ReS	Lung Ultrasound Reaeration Score
LV	Left ventricle
LVR	Lung volume recruitment
MAC	Manually assisted cough
MDT	Multidisciplinary team
MEP	Maximal expiratory pressure
mg/h	Milligram per hour
MI	Mechanical insufflations
MIC	Maximum insufflation capacity
MI-E	Mechanical Insufflation-Exsufflation

MIP	Maximal inspiratory pressure
mL/kg	Milliliters to kilograms
mm/Hg	<i>Millimeters</i> of mercury
mmol/L	Millimoles per liter
MODS	Multiple organ dysfunction syndrome
MOF	Multiple organ failure
MRF	Maugeri Respiratory Failure questionnaire
MV	Mechanical ventilation
NAVA	Neurally adjusted ventilatory assist
NC	Nasal cannula
NEX	Distance of nose tip earlobe and processus xyphoideus
NIMV	Noninvasive mechanical ventilation
NIOV	Noninvasive open ventilation
NIPSV	Noninvasive pressure support ventilation
NIV	Noninvasive ventilation
NIV-BF	Noninvasive positive pressure facilitated bronchofiberscopy
NMBAs	Neuromuscular blocking
NMD	Neuromuscular disease
NPPV	Noninvasive positive pressure ventilation
NPV	Negative pressure ventilation
NREM	Non-rapid eye movement
NT-proBNP	N-terminal pro-brain natriuretic peptide
NVS	Noninvasive ventilatory support
O ₂	Oxygen
O ₂ -LT	Oxygen long-term therapy
O ₂ T	Oxygen therapy
OCS	Oral corticosteroids
OD	Oxygen desaturation
ODI	Oxygen desaturation index
OHS	Obesity-hypoventilation syndrome
OR	Odds ratio
OSA	Obstructive sleep apnea
P/F-PaO ₂ /FiO ₂	Ratio of PaO ₂ to fraction of inspired oxygen
P/F ratio	Partial pressure of arterial oxygen/fraction of inspired oxygen ratio
P/I Index	Ratio of EADi peak value and EADi inspiratory AUC
PaCO ₂	Partial pressure of arterial carbon dioxide
PaCO ₂	Arterial carbon dioxide tension
Pal	Alveolar pressure
PaO ₂	Arterial oxygen partial pressure
PAV	Proportional assist ventilation
Paw	Airway pressure
PAWP	Pulmonary arterial wedge pressure
PBW	Predicted body weight
PC-BIPAP	Control pressure – Bilevel positive airway pressure

PCA	Patient control analgesia
PC-BiPAP	Pressure control bilevel positive airway pressure
PCF	Peak cough flow
pCO ₂	Carbon dioxide tension
PCV	Pressure control ventilation
PEEP	Positive end-expiratory pressure
PEEPi	Intrinsic positive end-expiratory pressure
PEF	Peak expiratory flow
PE	Pulmonary embolism
PetCO ₂	End-tidal CO ₂
PFTs	Pulmonary Function Tests
pH	Potential of hydrogen
PH	Pulmonary hypertension
pNIV	Portable noninvasive ventilation
pO ₂	Peripheral oxygen saturation
PPC	Postoperative pulmonary complications
PPE	Personal protective equipment
Ppl	Pleural pressure
PPV	Positive pressure ventilation
PR	Pulmonary rehabilitation
PVR	Pulmonary vascular resistance
PS	Pressure support
PSG	Polysomnography
P-SILI	Patient self-induced lung injury
PSV	Pressure support ventilation
PtcCO ₂	Transcutaneous carbon dioxide
pts	Patient/s
PVA	Patient–ventilator Asynchrony
PVD	Patient ventilator dyssynchrony
PY	Pack year
Raw	Airway resistance
RCT	Randomized clinical trial
REM	Rapid eye movement
RF	Respiratory failure
RHDCU	Respiratory high-dependency care unit
RICU	Respiratory Intensive Care Unit
ROM	Range of motion
RR	Respiratory rate
RRT	Renal replacement therapy
RV	Residual volume
RVent	Right ventricle
RVSP	Right ventricular systolic pressure
S/T Mode	Spontaneous/Timed Mode
SaO ₂	Oxygen saturation
SAPS II	Simplified Acute Physiology Score II

SAPS	Simplified Acute Physiology Score
SAPS3-CNIV	Simplified Acute Physiology Score 3-Customized NIV
SatO ₂	Arterial oxygen saturation
SB	Spontaneous breathing
SD	Swallowing disorders
SDB	Sleep disordered breathing
SGRQ	St George's Respiratory Questionnaire
SID	Strong ion difference
SMA	Spinal muscular atrophy
SMARD1	Spinal muscular atrophy with respiratory distress type 1
SOFA Score	Sequential Organ Failure Assessment Score
SPN-CPAP/PS	Spontaneous - Continuous positive airway pressure or Pressure support ventilation
SpO ₂	Peripheral oxygen saturation
SRBDs	Sleep-related breathing disorders
SrH	Sleep-related hypoventilation
SrHDs	Sleep-related hypoventilation disorders
SRI	Severe Respiratory Insufficiency questionnaire
StO ₂	O ₂ saturation
SVA	Subject ventilator asynchrony
T90	Time spent SpO ₂ <90%
TAPSE	Tricuspid annular plane systolic excursion
TB	Tuberculosis
TBI	Traumatic brain injury
TcCO ₂	Transcutaneous carbon dioxide
TEE	Transesophageal echocardiography
Ti	Inspiratory time
TI	Thickening fraction
TLC	Total lung capacity
TRV	Tricuspid regurgitation velocity
TTE	Transthoracic echocardiography
TV	Tidal volume
Tv	Tricuspid valve
UIP	Usual interstitial pneumonia
Va/Q	Ratio of ventilation to perfusion
VAP	Ventilator-associated pneumonia
VAPS	Volume-assured pressure support
VATS	Video-assisted thoracoscopic surgery
VC	Vital capacity
VCI	Vena cava inferior
VCV	Volume-controlled ventilation
VDd	Dead space of the mask
VDdyn	Dynamic dead space
VDph	Physiologic dead space
VIDD	Ventilator-induced diaphragmatic dysfunction

VILI	Ventilator-induced lung injury
VPF	Ventilatory pump failure
VPW	Vascular pedicle width
VRG	Ventral respiratory groups
VS	Versus
V _t	Tidal volume
WBC	White blood cell count
WOB	Work of breathing
WSS	Woodhouse-Sakati syndrome
ΔP	Pressure change
ΔV	Volume change
μL	Microliter
% pred	Percent of predicted value

List of Videos

- Video [1.1](#) Case Clinics Monitoring: Part 1.1
- Video [1.2](#) Case Clinics Monitoring: Part 1.2
- Video [1.3](#) Case Clinics Monitoring: Part 1.3
- Data [4.1](#)
- Data [9.1](#)
- Data [9.2](#)
- Data [9.3](#)
- Data [13.1](#)
- Data [14.1](#)
- Data [16.1](#)
- Data [17.1](#)
- Data [18.1](#)
- Data [20.1](#)
- Data [22.1](#)
- Data [24.1](#)
- Data [25.1](#)
- Data [26.1](#)
- Data [27.1](#)
- Data [28.1](#)
- Data [29.1](#)
- Data [30.1](#)
- Data [31.1](#)
- Data [32.1](#)
- Video [34.1](#) Non-invasive pressure support ventilation. In the upper side there is the pressure—time scalar and the flow—time scalar. The ventilator (Puritan BennettTM 840) was set with 12 cmH₂O of pressure support to give 13 L/min of total volume with a PEEP of 8 cm H₂O
- Video [34.2](#) Continuous positive airway pressure. In the upper side there is the pressure—time scalar and the flow—time scalar. The ventilator (Puritan BennettTM 840) was set without pressure support, the patient respiratory drive gives 10 L/min of total volume with a PEEP of 8 cm H₂O. It

is important to note that without increasing the pressure in the pressure—time scalar, there is movement of flow in the flow—time scalar. This mode can be used in patients with correct respiratory drive

Data [34.3](#)

Data [35.1](#)

Data [36.1](#)

Data [38.1](#)

Data [41.1](#)

Data [43.1](#)

Data [44.1](#)

Data [47.1](#)

Data [48.1](#)

Data [53.1](#)

Data [55.1](#)

Data [57.1](#)

Data [58.1](#)

Video [58.1](#)

Video [58.2](#)

Data [59.1](#)

Data [60.1](#)

Data [61.1](#)

Electronic Supplementary Material is available in the online version of the related chapter on SpringerLink: <https://doi.org/10.1007/978-3-030-71298-3>

Part I
Clinical Cases in Noninvasive
Ventilation: Interfaces, Methodology

Chapter 1

Facemask and Total Face Mask



Edoardo Piervincenzi, Giorgio Zampini, and Daniela Perrotta

1.1 Introduction

Avoiding endotracheal intubation in adult and pediatric population has undiscussed advantage.

Nowadays there is a great development by the companies of new masks and physicians have a wide selection of interfaces available.

At the same time, there are few recommendation about which interface are better than other in each clinical situation, and data about tolerance and efficacy are lacking especially for paediatric patients.

Every ICU anyway, should have several types of mask/interface to provide a tailored therapy on each patient to provide the best possible comfort and efficacy during NIV therapy administration.

Facemask (oro-nasal mask) and full-face mask are both valid instruments to provide non-invasive positive pressure ventilation therapy.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/978-3-030-71298-3_1.

E. Piervincenzi (✉)

Anesthesia and Intensive Care Medicine, Sapienza University of Rome, Rome, Italy
e-mail: edoardo.piervincenzi@policlinicogemelli.it

G. Zampini

Anesthesia and Intensive Care Medicine, Cagliari University, Cagliari, Italy
e-mail: Giorgio.zampini@opbg.net

D. Perrotta

Pediatric Intensive Care Unit, Children's Hospital "Bambino Gesù", Rome, Italy
e-mail: Daniela.perrotta@opbg.net

Also the helmet has shown over the years to be a valid alternative to supply NIV with some precautions in the setting of the mechanical ventilator.

In this chapter, the main aspects of the NIV delivered through masks will be analyzed, NIV will be intended as a ventilation with an inspiratory and an expiratory pressure level both generated by the mechanical ventilator. CPAP therapy or HFNC will not be treated as topics in this paper [1–6].

1.2 NIV-Mask

1.2.1 Characteristics

A first differentiation must be considered between vented and non-vented mask, this will lead to the use of different circuits, different ventilators with intrinsic characteristics; all aspects that have repercussion on NIV supply (see Fig. 1.1).

In ICU/PICU usually are preferred non-vented mask with double tube circuits due to large diffusion of ICU-ventilators instead of Home Care Ventilator.

But in some patient especially in chronic ones, Home Care-Ventilators are more tolerated and offer a lot of interesting options with particular ventilation modalities.

It is superfluous to point out that unvented interfaces cannot absolutely be used on single-limb circuits because it would cause enormous damage due to an impossible expiration.

Likewise, the vented interfaces cannot be used on double-limbs circuits due to the enormous pressure losses that would result.

The non-vented Oro-nasal or full-face masks with ICU ventilator is more effective in dyspnoeic patients due to a lower amount of risk of rebreathing CO₂ (see Figs. 1.2 and 1.3).

Fig. 1.1 Different connector for vented single limb circuit (a) and for non-vented double limb circuit (b)



Fig. 1.2 Example of nasal mask



Fig. 1.3 Example of oronasal: fullface masks



The nasal masks or nasal pillows can be used only in cooperative non-dyspnoeic adult patient or in small infants that have still nasal breathing, the patient usually better accepts these masks than the other interfaces, but the power in gas exchange improvement is low.

In collaborating non-dyspnoeic adult patient however, any interface that is comfortable for the patient can be reasonably used only if, however, we know its characteristics and strategies to get better its effectiveness.

The success or not of NIV therapy depend on the capability to reduce amount of WOB and to increase alveolar minute ventilation.

Leaks and patient-ventilator asynchrony are the two main negative determinants responsible for the failure of the NIV.

An interesting data from literature is that seems to have more weight on the outcome the choice of a correct interface rather than the ventilation mode.

In addition, the poor tolerance, for claustrophobia, for an uncomfortable interface that develops too much pressure on the skin inevitably leads to an excessive discomfort and therefore to the interruption of the treatment.

Patient comfort play a key-role in ensuring continuous therapy without interruption thus allowing effective alveolar recruitment and adequate rest of the respiratory muscles.

Therefore, is crucial to choose masks that have adequate fixing systems capable of distributing the pressures and possessing well adherent but at the same time soft cushion (see Fig. 1.4).

From a physiological point of view, any type of mask increase the dead space but peep level correctly set could gain a better CO₂ washout and cut down the risk of rebreathing.

Saatci et al. have investigated the properties in terms of dead space of several facemask.

The different design of each mask could influence not only the absolute but also the dynamic dead space [7]. R. Fodil et al. tested several numbers of interfaces comparing them in term of dead space and his clinical impact.

The different interfaces available have shown to be all, each with its own small differences and peculiarities, a good way to delivering NIV therapy. The airway pressure, neuromuscular drive, inspiratory muscle effort, work of breathing (WOB), arterial blood gases does not shown great difference [8].

With the appropriate setting of the mechanical ventilator, also the differences in terms of WOB can be effectively overcome.

This paper, with an elegant fluid-dynamics study, show how the effective dead space called interface dead space it's not equivalent to real interface volume.

This means that, in this bench study, with a normal adult tidal volume the bigger interface does not entail a significant exhaled gas rebreathing.

The authors explain this phenomenon by demonstrating that when the interface has a large internal volume, as in the case of the helmet, each single breath influences the variation of internal gases by a small percentage and convective flux inside

Fig. 1.4 Different type of headgears



has a relative role. When the interface has smaller internal volume (much more near to V_t), a predominant role in the variation of gas composition is assumed by the convective flow that develops inside and the real dead space is almost the same to internal volume (see Table 1.1).

If this is true in adult, with a tidal volume in the order of hundreds of milliliters, it may not be equally true in the child although there is no currently experimental strong data to verify it.

In this paper the authors suggest that, for extremely low VT, maybe the better interface to reduce CO_2 and to prevent gas rebreathing are Helmet. Unfortunately, the Helmet, with a low tidal volume ventilation has enormous problems in term of sensivity of inspiratory trigger and in synchronization.

Davide Signori et al. have shown, in another paper, how the use of non-vented double-tube interfaces significantly reduce CO_2 rebreathing during NIV and the presence of a flow-by amplified this effect [10].

In a bench-study by Conti et al. has been studied in details the synchronization and the interaction between patient and ventilator with different paediatric interfaces during PSV in a mixed obstructive restrictive model.

PSV ventilation present several problems of asynchrony/interaction especially for high respiratory frequencies.

From this study emerge that Helmet has the worst patient interaction, especially during high respiratory frequency (>30 rr) even in a normal lung model in PSV.

All the results available to date seem to indicate the use of a mask as a preferential delivery strategy in the NIV, in the pediatric population, albeit with the theoretical limits linked to rebreathing as explained above [9].

Finally, as emerged from the PEMVECC, to date, there are no strong date to recommend method or timing for NIV in paediatric population.

Despite the bench studies, there are not enough RCTs to define if an interface is better than another one.

As recommended in adult, it should be used the more fitting interface with less percentage of leaks monitoring patient-ventilator synchrony to improve efficacy and comfort [11, 12].

Table 1.1 Characteristics of principal interface to erogate NIV

	Nasal mask	Oro-nasal mask	Full face mask	Helmet
Statical dead space	–	–/+	+	+++
Claustrophobia	–	–/+	+	++
Secretion clearance	++	+	+	–/+
Aspiration risk	–	+	+	+
Flow resistance	++	–/+ (depends on prevalence of nasal breathing or not)	–/+ (depends on prevalence of nasal breathing or not)	–
Patient-ventilator interaction	–/+	++	++	–

In adult such as in paediatric population, success of NIV is even closely related to underlying disease.

In fact, is particularly effective in cardiogenic oedema or in acute exacerbation of chronic respiratory failure, it is much less effective in respiratory failure secondary to oncologic disease or to ARDS.

NIV is also used efficiently as a ventilatory therapy for respiratory distress occurring after extubation both in adults and in children.

The keystone of a successful treatment is a well adaptation of the patient with the NIV: few asynchronies, good comfort and small leaks associated to a good reduction in WOB and in an improvement in gas exchange.

If all this is not achieved in a rather short time the NIV is in the adult that in the child will have high failure rates that will inevitably lead to intubation.

1.3 Bronchopulmonary Displasia

Northway et al. described BPD in 1967 for the first time as a diffuse lung disease in a premature lung.

Low volumes and a progression to chronic disease heterogeneous with infiltrates and hyperinflation areas with sponge-like or cystic lesion inside characterized the disease.

BPD now is considered a chronic lung disease typically of premature child with an abnormal distribution of small pulmonary vessels with a hyper-reactive arteriolar tone. These anatomic-pathological modifications lead to pulmonary hypertension and right ventricular hypertrophy.

BPD is still the most frequent disease for premature infant born before the 30th gestational week and persist as chronic respiratory disease in childhood.

To date, there are lacking data from literature about consequences and late outcomes of this disease in childhood, however we know how these children are much more susceptible to respiratory infective events and how they often need MV to overcome these exacerbation.

Going on with age, the disease tends to develop fewer exacerbations episodes even if, from the latest data in the literature, it seems to be responsible for permanent pathological changes in the lungs like pulmonary hypertension, asthma-like symptoms and a permanent compromised lung function [13–15].

Clinical Case

BPD patient 2 years and 4 months old.

Chronic therapy since 4 months ago with Sildenafil, PEG on 2018.

No requirement of O₂ home therapy.

N1H1 pulmonary infection on January 2019.

At presentation on ED in March 2019, there was bilateral crackles, a SpO₂ of 90% and on chest x-ray hyper-insufflation, atelectasis zones and air bronchogram sign.

Viral PCR on tracheal aspirate positive for coinfection from Adenovirus and Metapneumovirus.

Was diagnosed a superior right lobar and left medium-basal pneumonia.

EGA on room air: pH 7,29, PaO₂ 41, PaCO₂ 52, BE -4, Lac 1.2.

First line therapy was high flow nasal oxygen with FiO₂ 40% at 2 L/kg/min, aerosol therapy with beta2 agonist and ipratropium. In addition, was started a broad-spectrum antibiotic therapy with Amoxicillin/clavulanate plus Claritromicin ev.

EGA after 2 h of oxygen therapy: pH 7,28, PaO₂ 65, PaCO₂ 54, BE -4.2, Lac 1.0.

Despite therapy after 24 h, there was no improvement of EGA and respiratory mechanics; moreover, indexes of phlogosis and neutrophilia raised up so it was decided to admit the patient in PICU.

Was performed an Echocardiography that shown increased right side pressure so we started a full face NIV, diuretics therapy and Sildenafil ev. beyond the therapies already in progress.

NIV treatment was started with an oro-nasal face alternating it with a full-face mask every 8 h to prevent pressure sore in PRVC controlled ventilation with peep level of 7 cmH₂O, a FiO₂ of 40% and a target volume of 7 mL/kg with a Servo-u ventilator.

EGA after 6 h of NIV: pH 7.36, PaO₂ 95, PaCO₂ 41, Be -1.3, Lac 0.9.

Two days after we received the result from microbiological tracheal culture positive for E. Coli and antibiotic therapy was changed with Meropem instead of Amoxicilline/clav.

After 4 days, in anticipation of a shift of the patient to a sub-intensive respiratory therapy unit, the ventilator strategy was modified in an S/T ventilation (ipap 16 epap 6 with a FiO₂ of 40% 35 rr) with an home care ventilator TRILOGY 200®.

The patient has been ventilated with a vented oronasal interface cycling NIV with HFNC allowed a progressive re-autonomization of spontaneous respiratory activity.

During the whole period in PICU, active respiratory physiotherapy was performed to increase airway secretions clearance prevent respiratory muscle atrophy and improve recovery.

Another 3 days of non-invasive mechanical ventilation in PICU allowed an improvement of the exchanges such as to be able to discharge the patient in the respiratory sub-intensive ward with a successful ventilation weaning after another 2 days of HFNC therapy and 2 on low flux oxygen nasal cannula.

Patient was successfully discharged from Hospital with a SpO₂ of 93% and a perfectly compensated pH without needing of oxygen.

Key Teaching Points

Strategy in NIMV with mask.

- The choice of right size interface for each patient is the first step to guarantee better tolerance and an optimal ventilator assistance.

An incorrect mask size can lead to huge leaks hard to manage (compensate) even for ventilators with NIV algorithm.

Moreover too big or too small mask, displacing easily, cause discomfort for the patient and less tolerability.

Even the knows of ventilator available to provide NIV in ICU is fundamental to a successful treatment, each one has own strengths and weaknesses characteristic in NIV therapy.

- Do not try to make a mask fit by tightening the headgear, this will only lead to a lower tolerance of the mask
- Even the best mask after some hours creates discomfort due to the constant pressure applied on the facial tissues up to the formation of real pressure sore especially with high peep level.

To ensure a long-term NIV tolerance it is important a constant daily rotation between at last two different interface available having different shape and then different pressure surface.

- In chronic pulmonary disease (in children as well as in adults), the assisted ventilation modalities are to prefer. These patient has already less respiratory muscle reserve because they are already chronically fatigued and even few days of controlled ventilation could compromise muscle function make weaning process much more difficult if not impossible.
- Physical rehabilitation and respiratory physiotherapy have a crucial role to help in airway secretion clearance and to maintain adequate physical conditioning to start respiratory weaning when clinical condition improve.
- A gradual passage from much more assisted to less assisted NIV and then from NIV to CPAP or HFNC is mandatory to successfully weaning process, especially in chronic disease. This variegate subset of illness has in common the difficulty of restoring the initial condition, tending to worsen after every single episode of exacerbation.

References

1. Conti G, Piastra M. Mechanical ventilation for children. *Curr Opin Crit Care*. 2016;22(1):60–6.
2. Gregoretti C, Pelosi P, Chidini G, Bignamini E, Calderini E. Non-invasive ventilation in pediatric intensive care. *Minerva Pediatr*. 2010;62(5):437–58.
3. Najaf-Zadeh A, Leclerc F. Noninvasive positive pressure ventilation for acute respiratory failure in children: a concise review. *Ann Intensive Care*. 2011;1:15.

4. Bello G, De Pascale G, Antonelli M. Noninvasive ventilation. *Clin Chest Med.* 2016;37(4):711–21. <https://doi.org/10.1016/j.ccm.2016.07.011>. Epub 2016 Sep 10. Review.
5. Pisani I, Comellini V, Nava S. Noninvasive ventilation versus oxygen therapy for the treatment of acute respiratory failure. *Expert Rev Respir Med.* 2016 Jul;10(7):813–21.
6. Bello G, Ionescu Maddalena A, Giammatteo V, Antonelli M. Noninvasive options. *Crit Care Clin.* 2018;34(3):395–412. <https://doi.org/10.1016/j.ccc.2018.03.007>. Epub 2018 May 4.
7. Saatci E. Dynamic dead space in face masks used with noninvasive ventilators: a lung model study. *Eur Respir J.* 2004 Jan;23(1):129–35.
8. Fodil R, Lellouche F, Mancebo J, Sbirlea-Apiou G, Isabey D, Brochard L, Louis B. Comparison of patient–ventilator interfaces based on their computerized effective dead space. *Intensive Care Med.* 2011 Feb;37(2):257–62.
9. Conti G, et al. Influence of different interfaces on synchrony during pressure support ventilation in a pediatric setting: a bench study. *Respir Care.* 2015;60(4):498–507.
10. Signori D, Bellani G, Calcinati S, Grassi A, Patroniti N, Foti G. Effect of face mask design and flow-by on rebreathing during noninvasive ventilation. *Respir Care.* 2019;64(7):793–800.
11. Marohn K, Panisello JM. Noninvasive ventilation in pediatric intensive care. *Curr Opin Pediatr.* 2013;25(3):290–6.
12. Jobe AH. Mechanisms of lung injury and bronchopulmonary dysplasia. *Am J Perinatol.* 2016;33:1076–8.
13. Jobe AH, Bancalari E. Definition of bronchopulmonary dysplasia: diagnostic criteria. Reprinted with permission of the American Thoracic Society. American Thoracic Society; 2016.
14. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. *Am J Respir Crit Care Med.* 2001;163:1723–9.
15. Davidson LM, Berkelhamer SK. Bronchopulmonary dysplasia: chronic lung disease of infancy and long-term pulmonary outcomes. *J Clin Med.* 2017;6(1):E4.

Chapter 2

Helmet



Giorgio Zampini, Edoardo Piervincenzi, and Daniela Perrotta

2.1 Introduction

The management of respiratory distress in adults and in children is challenging for intensivists and pediatricians; proper treatment is crucial to avoid death and long-term disabilities. When respiratory distress is confirmed, its treatment requires correction and improvement of gas exchange, followed by the diagnosis of the underlying causes and complications [1].

Several studies have showed that Helmet CPAP has a high efficiency in resolving respiratory distress. This was mostly due to the effect of CPAP on alveolar extension, which causes an increase of the alveolar surface responsible for blood gas exchange.

Supplementary Information The online version contains supplementary material available at [\[https://doi.org/10.1007/978-3-030-71298-3_2\]](https://doi.org/10.1007/978-3-030-71298-3_2).

G. Zampini (✉) · D. Perrotta
Pediatric Intensive Care Unit, Children’s Hospital “Bambino Gesù”, Rome, Italy
e-mail: Giorgio.zampini@opbg.net; Daniela.perrotta@opbg.net

E. Piervincenzi
Anesthesia, intensive care and toxicology Department, Fondazione A.Gemelli IRCSS, Rome, Italy
e-mail: edoardo.piervincenzi@policlinicogemelli.it

2.2 Helmet Interface

The helmets are made by a soft transparent plastic hood built on a hard plastic ring. The base of the plastic ring is connected with a silicon/polyvinyl chloride soft collar that provides a pneumatic seal at the neck, while the hood contains the patient's entire head.

The collar provides a good seal without major compression at contact points. The lack of pressure points on the face avoids skin necrosis and pain, reduces discomfort, and improves patient tolerance.

The seal around the neck allows the use of the helmet also in patients with difficult anatomical situations that commonly do not allow the use of a facemask.

Different companies produce various types and sizes of helmets, each provided with various fixing and safety features. The choice of the right size generally depends on the circumference of the neck.

The helmet can be used as an alternative interface to the face mask during the NIV (Fig. 2.1) or it can be used to deliver an air flow with high oxygen concentration and a PEEP if simply connected to an air blender (Fig. 2.2).

When this is used instead of the face mask it is connected via an inspiratory branch and an expiratory branch to the mechanical ventilator. If you switch from a NIV therapy with a mask to a helmet it is good, as underlined by numerous works, to increase the inspiratory pressure by a 20%. This is because the interface of the helmet has a greater volume and different structural characteristics.

There are little difference in intrinsic characteristics between helmet designed for CPAP (bigger inner volume and softer hood) and helmet designed for NIV (smaller inner volume and harder hood to transmit better the delta pressure).

Fig. 2.1 Helmet for NIV therapy connected with two branch to the mechanical ventilator



Fig. 2.2 Helmet for CPAP therapy connected with one branch to the mechanical ventilator or gas blender



Table 2.1 How set gas flow to reach desired FiO₂ with a gas blender

Total Flow L/min	5	5	5	10	10	10	10	10	15	15	15	15	15									
Air L/min	4	3	2,5	9	8	7	6	5	14	12	11	9	7,5									
O ₂ L/min	1	2	2,5	1	2	3	4	5	1	3	4	6	7,5									
FiO ₂ %	37 %	53 %	61 %	29 %	37 %	45 %	53 %	60 %	30 %	37 %	42 %	53 %	60 %									
Total Flow L/min	20	20	20	20	20	25	25	25	25	25	25	25	30	30	30	30	30	30	30			
Air L/min	18	17	16	14	13	22	20,5	19	17,5	16	14	12,5	26,4	24,5	22,5	21	19	16,5	15			
O ₂ L/min	2	3	4	6	7	3	4,5	6	7,5	9	11	12,5	3,6	5,5	7,5	9	11	13,5	15			
FiO ₂ %	29 %	33 %	37 %	45 %	49 %	30 %	35 %	40 %	45 %	49 %	56 %	60 %	30 %	35 %	41 %	45 %	50 %	57 %	60 %			
Total Flow L/min	35	35	35	35	35	35	35	40	40	40	40	40	40	40	40	45	45	45	45	45	45	45
Air L/min	30,5	28,5	26,5	24,5	22	17,5	17,5	35	32,5	30,5	28	25	22	20	39,5	37,5	34,5	31,5	28,5	25	22,5	
O ₂ L/min	4,5	6,5	8,5	10,5	13	15,5	17,5	5	7,5	10,5	12	15	18	20	5,5	8	11	13,5	16,5	20	22,5	
FiO ₂ %	31,5%	36 %	40 %	45 %	50 %	56 %	60 %	31 %	36 %	41 %	45 %	51 %	56 %	60 %	31 %	35 %	40 %	45 %	50 %	56 %	60 %	
Total Flow L/min	50	50	50	50	50	50	50	55	55	55	55	55	55	55	60	60	60	60	60	60	60	
Air L/min	44,5	41	38	35	32	28,5	25	49	45,5	41,5	38	34,5	31	27,5	53,5	49,5	45	41,5	38	34,5	30,5	
O ₂ L/min	5,5	9	12	15	18	21,5	25	6	9,5	13,5	17	20,5	24	27,5	6,5	10,5	15	18,5	22	25,5	30	
FiO ₂ %	30 %	35 %	40 %	45 %	50 %	55 %	60 %	30 %	35 %	40 %	45 %	50 %	55 %	60 %	30 %	35 %	40 %	45 %	50 %	55 %	60 %	

The volume delivered for each act, the respiratory frequency, the sensitivity of the cycling, the PEEP and the FiO₂ will be regulated by the mechanical ventilator options during bilevel ventilation.

During CPAP therapy we set only PEEP level, FiO₂ and liters per minute delivered into the helmet, the respiratory rate and the tidal volume is regulated by the patient.

Considering the significant increase in dead space and the very high compliance of the device may result in inconsistencies between the set volume and the volume actually delivered. This is shown even more clearly when the volumes set are very small [2].

For this reason the use of the helmet is currently reserved for NIV set in assisted ventilation with two pressure levels or CPAP therapy.

When for therapeutic purposes it is only necessary to set a higher FiO₂ together with a PEEP, it is possible to connect the helmet through its inlets port directly to the air blender.

The total air flow and the oxygen flow are regulated as indicated in the table to reach the total air flow and the desired oxygen concentration (Table 2.1).

Another port provide for expiratory exit; a threshold valve is mounted here to generate PEEP.

In addition, there is a pressure release valve which opens in case of sudden absence of air flow to prevent asphyxia in case of technical malfunction.

2.3 Bronchiolitis

Among etiological causes of respiratory distress in childhood, bronchiolitis is the most common etiology in infants <1 year of age admitted to the hospital [1, 3].

Several studies showed that bronchiolitis represents the greatest worldwide cause [4, 5] of infant hospitalization and the 17.1% of all non-elective pediatric ICU admissions [3].

Moreover, it is estimated that 1–3% of hospitalized infants will require treatment in an intensive care unit, especially when risk factors are present [5], and 7–9% of these infants require ventilatory support [6, 7].

The most common symptoms include coughing, wheezing, difficulty eating and sleeping, and apneas.

The principal underlying cause of Bronchiolitis is the respiratory syncytial virus (RSV) infection. It mostly affects children from 0 to 2 years [8] and 1–3% of the worldwide infant population is hospitalized for bronchiolitis during winter months [4, 5]. Management of bronchiolitis mostly involves supportive care that include rehydration and oxygen supplementation [9].

Inflammation of the infant's airways induces an increase in small airway resistance, causing increased ventilatory work [10].

In addition, the predominance of fast twitch muscle fibers in respiratory muscles accelerates fatigue and respiratory failure [11].

The most recent guidelines for management of infants with bronchiolitis and/or other causes of respiratory distress in hospitals emphasize the importance of oxygen therapy, respiratory support, and maintenance of hydration in hypoxia [12].

Respiratory support has traditionally been the cornerstone of intensive care settings and is usually provided by noninvasive techniques or intubation and mechanical ventilation [13–15].

The main common and effective noninvasive respiratory support methods in children with bronchiolitis and/or other etiologic causes, are the high-flow nasal cannula (HFNC) and CPAP, due to its ability to increase functional residual capacity with a reduction of apnoic episodes [16–18].

Both methods are efficient in improving the clinical conditions of patients with mild-to-moderate respiratory distress, although clinical response to helmet CPAP seems to be more efficient and rapid compared with that of HFNC [19].

During CPAP administration, the patient's airway is maintained throughout the respiratory cycle at a selected constant pressure (CPAP) higher than the atmospheric pressure. This method improve respiratory mechanics and gas exchange in patients without neuromuscular diseases, and represent a good supportive therapy in patients with various forms of respiratory distress.

CPAP acts through improving arterial oxygenation and respiratory mechanics and reducing the patient's respiratory drive and effort.

Because the inspiratory effort creates a negative pressure inside the thorax, the ventricle afterload decrease. Accordingly, a decrease in inspiratory effort implies a reduction in the left ventricle afterload. Therefore, venous return and ventricle sizes are reduced with a parallel drop in the wall tension and myocardial oxygen consumption.

In patients with non-hydrostatic pulmonary edema, CPAP could improve gas exchange and respiratory mechanics, thereby increasing the end-expiratory lung volume and preventing alveolar collapse.

The alveolar extension provides a greater gas exchange surface, which improves the respiratory mechanics of ventilation and results in a consequent decrease of PaCO₂ in blood gas analysis [20].

Case Report

A 10 months old- infant, 3.5 kg, with negative familiar and medical history, arrived in Emergency Department complaining fever and dry cough from 3 days. At the moment of arrival she presented SpO₂ 88% and a blood gas analysis with pH 7.36, pCO₂ 44, pO₂ 60, Na+ 136; K+ 4.6, Cl- 106, glycaemia 124; Lac 0.8; Hb 11.1; EB - 0.5; HCO₃- 24.3.

The chest X-ray showed widespread thickening of the bronchial walls and of the peribronchovascular interstitium which is associated with the presence of two shaded areas of increased density localized respectively in the right para-cardiac site and left basal, of possible atelectasis significance.

The patient was admitted in the Intensive Observation Unit and HFNC 2 L/kg/ min., hydration, aerosol and antibiotic therapy were promptly started.

During the night an impairment of respiratory mechanic occurred with an increase of respiratory and cardiac rate, fever (T 38.6 C), wheezing and respiratory distress with nasal flaring, chest retractions and increase of respiratory effort.

The physical exam highlighted bilateral and diffuse crackles and a persistent several hypoxemia, despite maximal HFNC therapy, was detected at blood gas analysis.

The chest X-ray was repeated and showed that the areas of hypodiafania with an atelectasis significance appear increased. The widespread thickening of the bronchial walls remains bilaterally. Pleural cavities free from effusion. Cardio-mediastinal image within the limits, in axis.

The infant was admitted in Pediatric Intensive Care Unit and Helmet CPAP 40 L/ min FiO₂ 50% and peep valve set on 10 cm/H₂O was started.

CPAP was connected to a blender and an active humidification system that deliver a mixture of medical gas at the temperature of 32 °C.

The significant improvement in gas exchange, vital signs and sedation protocol, was reported in the Table 2.2.

Table 2.2 Patient improvement after Helmet CPAP therapy

Timing	pH	PaO ₂	P/F	PaCO ₂	Therapy	BP	HR	RR	Sedation
Pre CPAP	7.34	63	157	51	HFNC 40%	80/55	145	55	Morfine 0.01 mg/kg/h
1 h CPAP	7.36	117	228	51	CPAP 50% PEEP 10 cmH ₂ O	120/60	95	35	Dexdor 0.7 mcg/kg/h
12 h CPAP	7.42	128	256	44	CPAP 50% PEEP 10 cmH ₂ O	115/70	98	35	Dexdor 0.7–1.4 mcg/kg/h
24 h CPAP	7.40	178	356	42	CPAP 50% PEEP 10 cmH ₂ O	109/60	83	30	Dexdor 1.4 mcg/kg/h

Key Teaching Points

- NIV/CPAP erogated with Helmet is safe, well tolerated and effective to improve gas exchange and respiratory system workload.
- Humidity and temperature is two fundamental point to evaluate during CPAP with high fresh gas flow, especially in children, and if it is possible it should be used always an humidification system.
- When Helmet is used instead a mask to deliver NIV remember to set a 15–20% higher pressure to avoid CO₂ rebreathing and optimize respiratory workload
- Helmet is not a good interface to provide NIV in children due to excessive patient ventilator asynchronies and difficult triggering.

Hydration support was maintained with 14 mL/kg/h.

Waiting for microbiological results, corticosteroid and antibiotic therapy with ceftriaxone and clarithromycin were started.

Microbiological tests for *Chlamydia Pneumoniae*, *Mycoplasma Pneumoniae* and *Bordetella* spp. resulted negative, while nasopharyngeal aspirates were positive for Rhinovirus.

Serial radiological controls were made during the hospitalization in the intensive care unit and they showed a progressive improvement of pulmonary ventilation with a persistent upper right lobar hypodiafania and diffuse accentuation of the peribronchus-vascular texture.

Helmet CPAP showed a good patient's tolerance that allowed to a prolonged therapeutic effect with a significant beneficial effect on respiratory mechanics and gas exchange.

References

1. Green TP, Steinhorn DM. The treatment of acute respiratory failure in children: a historical examination of landmark advances. *J Pediatr*. 2001;139(4):604–8.
2. Patroniti N, Foti G, Manfio A, et al. Head helmet versus face mask for non-invasive continuous positive airway pressure: a physiological study. *Intensive Care Med*. 2003;29:1680–7.
3. Franklin D, Dalziel S, Schlappbach LJ, Babl FE, Oakley E, Craig SS, et al. Early high flow nasal cannula therapy in bronchiolitis, a prospective randomised control trial (protocol): a paediatric acute respiratory intervention study (PARIS). *BMC Pediatr*. 2015;15:183.
4. Midulla F, Nenna R. Bronchiolitis in infants and wheeze in preschool children. *Breathe*. 2011;8:32–7.
5. Everard M. Respiratory syncytial virus bronchiolitis and pneumonia. In: Taussig L, Landau L, editors. *Paediatric respiratory medicine*. Elsevier; 2009. p. 491–500.
6. O'Donnell R, Darowski M, the PICANet team. Acute respiratory failure in children under one year. In: *Paediatric Intensive Care Audit Network National Report 2004–2005; May 2006* [internet]. www.picanet.org.uk/Audit/Annual-Reporting/Annual-Report-archive/Picanet_national_report_2006.pdf. Accessed 29 Mar 2017.

7. Wang EEL, Law BJ, Stephens D. Pediatric investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. *J Pediatr*. 1995;126:212–9.
8. Mansbach JM, Piedra PA, Teach SJ, Sullivan AF, Forgey T, Clark S. Prospective multicenter study of viral etiology and hospital length of stay in children with severe bronchiolitis. *Arch Pediatr Adolesc Med*. 2012;166:700–6.
9. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gdomski AM, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. *Pediatrics*. 2014;134:1474–502.
10. Smyth RL, Openshaw PJ. Bronchiolitis. *Lancet*. 2006;368:312–22.
11. Keens TG, Bryan AC, Levison H, Ianuzzo CD. Developmental pattern of muscle fiber types in human ventilatory muscles. *J Appl Physiol Respir Environ Exerc Physiol*. 1978;44:909–13.
12. Oakley E, Borland M, Neutze J, Acworth J, Krieser D, Dalziel S, et al. Nasogastric hydration versus intravenous hydration for infants with bronchiolitis: a randomised trial. *Lancet Respir Med*. 2013;1(2):113–20.
13. Essouri S, Chevret L, Durand P, Haas V, Fauroux B, Devictor D. Non-invasive positive pressure ventilation: five years of experience in a pediatric intensive care unit. *Pediatr Crit Care Med*. 2006;7(4):329–34.
14. Javouhey E, Barats A, Richard N, Stamm D, Floret D. Non-invasive ventilation as primary ventilatory support for infants with severe bronchiolitis. *Intensive Care Med*. 2008;34(9):1608–14.
15. Lazner MR, Basu AP, Klonin H. Non-invasive ventilation for severe bronchiolitis: analysis and evidence. *Pediatr Pulmonol*. 2012;47(9):909–16.
16. Esposito S, Leone S. [Management of serious bacterial infections: general considerations]. *Infez Med* 2005;Suppl:3–6.
17. Zimmerman JE, Wagner DP, Knaus WA, Williams JF, Kolakowski D, Draper EA. The use of risk predictions to identify candidates for intermediate care units: implications for intensive care utilization and cost. *Chest*. 1995;108(2):490–9.
18. Chidini G, Piastra M, Marchesi T, De Luca D, Napolitano L, Salvo I, et al. Continuous positive airway pressure with helmet versus mask in infants with bronchiolitis: an RCT. *Pediatrics*. 2015;135(4):e868–75.
19. Vitaliti MD, Maria Concetta Vitaliti MD, Maria Carla Finocchiaro MD, et al. Randomized comparison of helmet CPAP versus high-flow nasal cannula oxygen in pediatric respiratory distress giovanna. *Respir Care*. 2017;62(8):1036–42. <https://doi.org/10.4187/respcare.05384>. Epub 2017 May 9.
20. Hilbert G, Gruson D, Vargas F, Valentino R, Gbikpi-Benissan G, Dupon M, et al. Non-invasive ventilation in immunosuppressed patients with pulmonary infiltrates, fever, and acute respiratory failure. *N Engl J Med*. 2001;344(7):481–7.

Chapter 3

Mouthpiece Ventilation



Jennifer Obi and Stephen M. Pastores

Case Report

A 34-year-old man with severe spinal injury following a motor vehicle accident and a 2-year history of nocturnal non-invasive ventilation (NIV) use via nasal mask was admitted to the hospital after being noted to be increasingly somnolent. In the emergency department he was found to be hypercapnic and hypoxemic. His mother reported excessive mouth leak. On examination, the patient was drowsy but easily arousable. A continuous face mask NIV was started with marked improvement. Once stabilized, he was discharged with a follow-up visit in the outpatient pulmonary clinic. He continued to use the nasal ventilation. At follow up review, respiratory acidosis reoccurred despite diurnal use of NIV.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/978-3-030-71298-3_3.

J. Obi

Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

e-mail: obi@mskcc.org

S. M. Pastores (✉)

Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Weill Cornell Medical College, New York, NY, USA

e-mail: pastores@mskcc.org

© Springer Nature Switzerland AG 2022

A. M. Esquinas (ed.), *Teaching Pearls in Noninvasive Mechanical Ventilation*, https://doi.org/10.1007/978-3-030-71298-3_3

Question: What is the appropriate next step in the management for this patient?

Answer: Continue NIV with intermittent daytime mouthpiece ventilation (MPV) alongside overnight NIV via nasal or face mask.

Following institution of MPV, control of respiratory failure was achieved. Most importantly, independent living was maintained. Intermittent MPV is practical and effective where the limits of ventilator tolerance have otherwise been reached. MPV may reduce the need for tracheostomy ventilation and this case serves as a reminder of the increasing NIV interface options available to clinicians.

3.1 Introduction

The mouthpiece ventilation (MPV) was introduced in the 1950s as a ventilatory mode that can be used as daytime ventilatory support in combination with other ventilatory modalities and interfaces for nocturnal noninvasive respiratory support.

Alveolar hypoventilation is a major complication of many neuromuscular diseases (NMDs). It occurs initially during sleep and subsequently extends into the daytime [1]. Nocturnal noninvasive positive pressure ventilation is the standard mode of initial management of alveolar hypoventilation in NMDs [2]; however as respiratory muscles weakness progresses, the ventilator-free breathing time is reduced significantly. When the number of hours of ventilator use per day exceed an arbitrarily defined threshold (e.g. >16 or 20 h), many practitioners consider transitioning to invasive ventilatory support via tracheostomy.

MPV has been used as an alternative to tracheostomy ventilation for patients requiring continuous ventilatory support for over 60 years. However, there is still a poor understanding of this method's benefits compared with other modalities. This chapter aims to highlight the indications, benefits and drawbacks of MPV.

3.2 Types of Mouth Piece Interfaces

There are two types of oral NIV interfaces: standard narrow mouthpieces with various degrees of flexion, which are held by the patient's teeth and lips; and custom-molded bite-plates (Fig. 3.1). Oral interfaces are used, especially in North America, for long-term ventilation of patients with severe chronic respiratory failure due to severe neurological dysfunction.

The mouth piece is placed between the patient's lips and held in place by lip-seal oral NIV interfaces. Intermittent MPV is practical and effective where the limits of ventilator tolerance have otherwise been reached. MPV may reduce the need for




Fig. 3.1 Mouthpiece interfaces: (a) 22 and 15 mm angled mouthpieces with adaptors. (b) Custom-molded bite-plates. (Reprinted with permission from Copyright Clearance Center.) (c) Mouthpiece interface connected to ventilator circuit

tracheostomy ventilation and this case serves as a reminder of the increasing options routinely available to NIV clinicians.

3.3 Indications

MPV is mainly indicated for patients with NMD and chronic respiratory failure when they develop daytime hypercapnia despite optimized nocturnal ventilatory support or when they manifest deteriorating daytime respiratory status with increasing ventilator dependence. In individuals with adequate bulbar muscle function but chronic respiratory muscle insufficiency, intermittent MPV can be an effective alternative to tracheostomy.

Majority of patients considered for MPV have already been using mechanical ventilation for several years. However, the experience of MPV is quite different and some patients may feel uncomfortable and express reluctance to continue. Hence, the application of MPV requires active participation from the patient, increased nursing time and longer periods of training [1].